Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $7.08B | $6.94B | +2.03% |
Cost of Revenue | $1.95B | $2.01B | -2.88% |
Net Income | $2.07B | $1.91B | +8.66% |
EPS (Basic) | $4.65 | $4.18 | +11.24% |
EPS (Diluted) | $4.65 | $4.18 | +11.24% |
SG&A Expense | $1.76B | $1.69B | +3.90% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $15.16B | $14.36B | +5.59% |
Current Assets | $6.58B | $6.28B | +4.79% |
Total Liabilities | $9.76B | $9.12B | +6.99% |
Current Liabilities | $1.81B | $1.7B | +6.17% |
Stockholders' Equity | $5.4B | $5.23B | +3.13% |
Cash & Equivalents | $2.08B | $1.71B | +21.59% |
Long-Term Debt | $7.07B | $6.57B | +7.53% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.01B | $2.05B | -1.81% |
Investing Cash Flow | $-582M | $-441M | -31.97% |
Financing Cash Flow | $-1.38B | $-1.92B | +28.20% |
Share Buybacks | $1.18B | $1.3B | -9.96% |
D&A | $366M | $374M | -2.14% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 29.2% | — | — |
ROE | 38.3% | — | — |
ROA | 13.7% | — | — |
Current Ratio | $3.643 | — | — |
Debt to Equity | $1.808 | — | — |
Other companies in Pharmaceuticals